Roche entered the obesity race late and is moving fast. The 2024 Carmot Therapeutics acquisition brought in CT-388 (now enicepatide) — a dual GLP-1/GIP receptor agonist that posted 22.5% placebo-adjusted weight loss in Phase 2. The 2025 Zealand Pharma partnership added petrelintide, the long-acting amylin analog that delivered double-digit weight loss with placebo-like tolerability in ZUPREME-1.
The Q1 2026 print clarified the pipeline cadence: ENITH 1 and ENITH 2, the two Phase 3 enicepatide obesity trials, were both initiated in Q1; the petrelintide+enicepatide fixed-dose combination Phase 2 starts mid-2026; and additional Phase 2 readouts for oral GLP-1 CT-996 are guided before year-end. Roche executives projected $9B in peak sales for the obesity pipeline and confirmed petrelintide and enicepatide ADA 2026 data presentations in June. On April 30, Zealand and Roche announced petrelintide's formal advancement to Phase 3 in chronic weight management.
Stories here cover the enicepatide and petrelintide programs, Carmot integration, and Q1/Q2 readouts. See #enicepatide, #petrelintide, and #zealand-pharma.
Zealand Pharma reported Q1 2026 revenue of DKK 34M against DKK 8M a year earlier and the DKK 17M analyst consensus — a more-than-2× beat on the recognition of Roche's $700M (DKK 4.5B) milestone payment tied to petrelintide's advancement into Phase 3. The board authorized a share buyback of up to DKK 1.3B. Net operating expenses came in at DKK 573M (below the DKK 679M consensus), and the company reaffirmed petrelintide Phase 3 obesity initiation in H2 2026. Petrelintide is the long-acting amylin analog that posted ~10.7% mean weight loss with placebo-like tolerability in ZUPREME-1; the Roche partnership combines it with the GLP-1/GIP enicepatide (CT-388) in a fixed-dose Phase 2 starting mid-2026. Shares rose 8.4% to DKK 344.
On the April 23 Q1 call and follow-up coverage, Roche clarified that its two Phase 3 enicepatide (CT-388) obesity trials — ENITH 1 and ENITH 2 — were both successfully initiated in Q1, with the dual GLP-1/GIP agonist on track to compete in the next-wave Phase 3 obesity readouts. Phase 2 reported 22.5% placebo-adjusted weight loss for enicepatide. Roche also confirmed the petrelintide+enicepatide fixed-dose combination Phase 2 will dose its first patient around mid-2026, pairing the Zealand-derived amylin analog (placebo-like tolerability, 10.7% mean weight loss in ZUPREME-1 at week 42) with Roche's stronger GLP-1/GIP backbone. Additional Phase 2 readouts for oral GLP-1 CT-996 are guided before year-end 2026.
Zealand Pharma announced April 29 that it and partner Roche have formally endorsed advancing petrelintide — a long-acting amylin analog suitable for once-weekly subcutaneous administration — into Phase 3 trials for chronic weight management, with initiation planned for H2 2026. The Phase 3 program will evaluate petrelintide as monotherapy and in combination with Roche's GLP-1/GIP receptor dual agonist enicepatide (CT-388). The decision follows positive Phase 2 ZUPREME-1 data showing up to 10.7% weight loss with placebo-like tolerability; petrelintide is now positioned as the lead non-GLP-1 obesity asset behind only Novo's CagriSema.
Roche reported Q1 2026 sales up 6% at constant exchange rates and used the earnings call to re-anchor its obesity strategy. Executives project $9 billion in peak annual sales from the emerging breast cancer pill plus four obesity candidates. Lead asset petrelintide (licensed from Zealand Pharma, ZUPREME-1 Phase 2 showed up to 10.7% weight loss with placebo-like tolerability) is positioned at a differentiated patient segment. CEO Schinecker said Roche is not investing in the first generation of obesity drugs, but the next — with petrelintide and CT-388 (enicepatide) data headed for ADA 2026.